高级检索
当前位置: 首页 > 详情页

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

文献详情

资源类型:
Pubmed体系:
机构: [1]Division of Epidemiology,Department of Health Sciences Research, Mayo Clinic, MN, USA [2]Division of Biomedical Statistics and Informatics , Department of Health Sciences Research, Mayo Clinic, MN, USA [3]Division of Medical Oncology , Department of Health Sciences Research, Mayo Clinic, MN, USA [4]Division of Pulmonary and Critical Care Medicine ,Department of Health Sciences Research, Mayo Clinic, MN, USA [5]Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan [6]School of Medicine, National Yang-Ming University, Taipei, Taiwan [7]Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan [8]Department of Science and Education, Guizhou Province People’s Hospital, Guiyang, Guizhou, China [9]School of Public Health and Management, Wenzhou Medical University, University Town, Chashan, Wenzhou, Zhejiang, China [10]Division of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China [11]Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan [12]Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA
出处:
ISSN:

摘要:
The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those who quit within the past 15 years. Our previous report found that two-thirds of newly diagnosed patients with lung cancer do not meet these criteria; they are reported to be either long-term quitters (≥15 years since quitting) or from a younger age group (age 50-54 years). We aimed to assess survival outcomes in these two subgroups. For this prospective, observational cohort study we identified and followed up patients aged 50-80 years with lung cancer, with a smoking history of 30 pack-years or more, and included both current smokers and former smokers who quit within the past 30 years. We identified patients from two cohorts in the USA: a hospital cohort (Mayo Clinic, Rochester, MN) and a community cohort (Olmsted County, MN). Patients were divided into those meeting USPSTF criteria (USPSTF group) versus those not meeting USPSTF criteria (long-term quitters or the younger age group). The main outcome was overall survival at 5 years after diagnosis. 5-year overall survival was analysed with and without matching age and pack-years smoked for long-term quitters. The USPSTF group was subdivided into two age subgroups (55-69 years and 70-80 years) for multivariable regression analysis. Between Jan 1, 1997, and Dec 31, 2017, 8739 patients with lung cancer were identified and followed up. Median follow-up was 6·5 (IQR 3·8-10·0) years, and median overall survival was 16·9 months (95% CI 16·2-17·5). 5-year overall survival was 27% (95% CI 25-30) in long-term quitters, 22% (19-25) in the younger age group, and 23% (22-24) in the USPSTF group. In both cohorts, 5-year overall survival did not differ significantly between long-term quitters and the USPSTF group (hospital cohort: hazard ratio [HR] 1·02 [95% CI 0·94-1·10]; p=0·72; community cohort: 0·97 [0·75-1·26]; p=0·82); matched analysis showed similar results in both cohorts. 5-year overall survival also did not differ significantly between the younger age group and the USPSTF group in both cohorts (hospital cohort: HR 1·16 [95% CI 0·98-1·38], p=0·08; community cohort: 1·16 [0·74-1·82]; p=0·52); multivariable regression analyses stratified by age group yielded similar findings. Patients with lung cancer who quit 15 or more years before diagnosis and those who are up to 5 years younger than the age cutoff recommended for screening, but otherwise meet USPSTF criteria, have a similar risk of death to those individuals who meet all USPSTF criteria. Individuals in both subgroups could benefit from screening, as expansion of USPSTF screening criteria to include these subgroups could enable earlier detection of lung cancer and improved survival outcomes. National Institutes of Health and the Mayo Clinic Foundation. Copyright © 2019 Elsevier Ltd. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
第一作者:
第一作者机构: [1]Division of Epidemiology,Department of Health Sciences Research, Mayo Clinic, MN, USA [3]Division of Medical Oncology , Department of Health Sciences Research, Mayo Clinic, MN, USA [5]Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan [6]School of Medicine, National Yang-Ming University, Taipei, Taiwan [7]Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
共同第一作者:
通讯作者:
通讯机构: [1]Division of Epidemiology,Department of Health Sciences Research, Mayo Clinic, MN, USA [12]Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA [*1]Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ 85259, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号